0000000000154238
AUTHOR
Mayer J
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia.Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of intravenous fludarabine (25 mg/m(2) per day) and cyclophosphamide (250 mg/m(2) per day) for the first 3 days of each 28-day treatment course with or without rituximab (375 mg/m(2) on day 0 of first course, and 500 mg/m(2) on da…
Effect of Physiologic Oscillatory Fluid Shear Stress on Engineered Heart Valve Tissue Formation.
It was previously demonstrated that combined flexure and flow in vitro conditioning augments engineered heart valve tissue formation using bone marrow-derived mesenchymal stem cells (MSC) seeded on polyglycolic acid (PGA)/poly-L-lactic acid (PLLA) blend nonwoven fibrous scaffolds (Engelmayr, et al., Biomaterials 2006; vol. 27 pp. 6083-95). Additionally, seeded scaffolds incorporated into a tissue engineered valve construct experienced significant increases in tissue formation rates with media supplementation (basic fibroblast growth factor [bFGF] and ascorbic acid-2-phosphate [AA2P]) and dynamic conditioning approximating pulmonary valve levels (Ramaswamy, et al., Biomaterials 2010; vol. 31…